Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.37 -0.32 (-0.55%)
Official Closing Price Updated: 7:00 PM EST, Dec 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
66 67 Next >
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is Bristol Myers' Dividend in Danger?
Should investors brace for a dividend cut? 
Via The Motley Fool
2 Beaten-Down Stocks to Buy and Hold for 10 Years
They offer plenty of upside and solid dividend growth. 
Via The Motley Fool
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders
Using these capture-the-dividend stock strategy for tactical traders can be profitable with high-yield blue-chips. 
Via InvestorPlace
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip
Bad news can be good news for an enterprising investor with a longer time horizon than the market's immediate reaction. 
Via The Motley Fool
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
From Bristol Myers Squibb
Via Business Wire
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
The sudden divergence has made clear some laggards who have ultra-low RSI readings that might just be too good to ignore. Here are 3 worth watching closely. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy. 
Via Benzinga
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Investing in high-yield dividend stocks under $50 is a low-risk strategy that can result in massive returns in time. 
Via InvestorPlace
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
From Bristol Myers Squibb
Via Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
From Bristol Myers Squibb
Via Business Wire
Uncover the Potential: 3 Discounted Stocks Ready for a Comeback
Investors should considered these discounted stocks to buy for generous returns due to current undervaluation and strong fundamentals. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock. 
Via The Motley Fool
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
The answer isn't great, but there's still reason to like Bristol Myers Squibb. 
Via The Motley Fool
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases 
From Editas Medicine, Inc.
Via GlobeNewswire
3 Top ETFs to Buy for Passive Income in May
These ETFs provide investors with above-average income streams. 
Via The Motley Fool
Topics ETFs
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
10 worst performing large-cap stocks last week: LKQ, MSCI, TXT, EDU, BMY, MANH, RS, META, LUV, NUE. Analysts cut price targets for many. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.